These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 1151137)
21. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels. Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304 [TBL] [Abstract][Full Text] [Related]
22. Urinary markers of bone resorption, pyridinoline and deoxypyridinoline, are increased in sickle cell patients with further increments during painful crisis. Nur E; Mairuhu W; Biemond BJ; van Zanten AP; Schnog JJ; Brandjes DP; Otten HM; Am J Hematol; 2010 Nov; 85(11):902-4. PubMed ID: 20882525 [TBL] [Abstract][Full Text] [Related]
23. [Fate of intravascularly released hemoglobin]. Furlan M Schweiz Med Wochenschr; 1973 Dec; 103(51):1852-5. PubMed ID: 4587170 [No Abstract] [Full Text] [Related]
26. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Talano JA; Hillery CA; Gottschall JL; Baylerian DM; Scott JP Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582 [TBL] [Abstract][Full Text] [Related]
27. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Olivieri NF; Koren G; Hermann C; Bentur Y; Chung D; Klein J; St Louis P; Freedman MH; McClelland RA; Templeton DM Lancet; 1990 Nov; 336(8726):1275-9. PubMed ID: 1978115 [TBL] [Abstract][Full Text] [Related]
28. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Wood JC; Tyszka JM; Carson S; Nelson MD; Coates TD Blood; 2004 Mar; 103(5):1934-6. PubMed ID: 14630822 [TBL] [Abstract][Full Text] [Related]
29. [Iron overload in sickle cell anemia : a study of 94 patients]. Hafsia R; Belakhal F; Ben Salah N; Gouider E; Elborgi W Tunis Med; 2011 Jun; 89(6):548-52. PubMed ID: 21681718 [TBL] [Abstract][Full Text] [Related]
30. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship. Silliman CC; Peterson VM; Mellman DL; Dixon DJ; Hambidge KM; Lane PA J Lab Clin Med; 1993 Jul; 122(1):48-54. PubMed ID: 8320490 [TBL] [Abstract][Full Text] [Related]
31. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. Inati A; Musallam KM; Wood JC; Sheikh-Taha M; Daou L; Taher AT Eur J Haematol; 2009 Dec; 83(6):565-71. PubMed ID: 19737308 [TBL] [Abstract][Full Text] [Related]
32. [Arterial pressure and urinary excretion of albumin in adults with sickle cell disease]. Foucan L; Salmi LR; Billy-Brissac R; Bourhis V; Bangou J Presse Med; 1995 Oct; 24(31):1428-32. PubMed ID: 8545331 [TBL] [Abstract][Full Text] [Related]
33. Albuminuria correlates with hemolysis and NAG and KIM-1 in patients with sickle cell anemia. Hamideh D; Raj V; Harrington T; Li H; Margolles E; Amole F; Garcia-Buitrago M; Ruiz P; Zilleruelo G; Alvarez O Pediatr Nephrol; 2014 Oct; 29(10):1997-2003. PubMed ID: 24890337 [TBL] [Abstract][Full Text] [Related]
34. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients. Boturao-Neto E; Marcopito LF; Zago MA Braz J Med Biol Res; 2002 Nov; 35(11):1319-28. PubMed ID: 12426631 [TBL] [Abstract][Full Text] [Related]
35. Deferiprone as an oral iron chelator in sickle cell disease. Voskaridou E; Douskou M; Terpos E; Stamoulakatou A; Meletis J; Ourailidis A; Papassotiriou I; Loukopoulos D Ann Hematol; 2005 Jul; 84(7):434-40. PubMed ID: 15809885 [TBL] [Abstract][Full Text] [Related]
37. Reassessment of the use of desferrioxamine B in iron overload. Propper RD; Shurin SB; Nathan DG N Engl J Med; 1976 Jun; 294(26):1421-3. PubMed ID: 1272274 [TBL] [Abstract][Full Text] [Related]